Drugs / UCMYM802
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06256055 | Mar 2024 → Mar 2025 | bile duct cancer, female breast carcinoma, malignant mesothelioma, malignant pancreatic neoplasm +2 | UTC Therapeutics Inc. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UCMYM802 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06256055 ↗ |
| Modality | Cell therapy | “Active ingredient：Anti-MSLN CAR+ T cell” NCT06256055 ↗ |
| Route | Intravenous | “1×10\^8\~2×10\^9 cells will be infused intravenously for 4 times.” NCT06256055 ↗ |
| Target | MSLN | “Active ingredient：Anti-MSLN CAR+ T cell” NCT06256055 ↗ |